2024
MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population
Woodard G, Kane E, Prince S, Blasberg J, Dhanasopon A, Boffa D, Mase V, Dacic S, Bader A, Detterbeck F. MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population. Journal Of Thoracic Oncology 2024, 19: s87. DOI: 10.1016/j.jtho.2024.09.156.Peer-Reviewed Original Research
2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changes
2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1Corrigendum to ‘Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy’ [Surgery 164/6 (2018) 1294–1299]
Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD. Corrigendum to ‘Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy’ [Surgery 164/6 (2018) 1294–1299]. Surgery 2019, 165: 1058. PMID: 30678871, DOI: 10.1016/j.surg.2018.12.014.Peer-Reviewed Original Research
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvivalOrganization, Teamwork and Quality of Care in Thoracic Surgery A Model for High Reliability Care Delivery.
Detterbeck FC, Zurich HB, Agarwal R, Blasberg JD, Boffa DJ, Delrossi EP, Finan ME, Hindinger KK, Kim AW, Pierson M. Organization, Teamwork and Quality of Care in Thoracic Surgery A Model for High Reliability Care Delivery. Connecticut Medicine 2017, 81: 5-12. PMID: 29782759.Peer-Reviewed Original Research
2016
Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer 2016, 103: 75-81. PMID: 28024700, DOI: 10.1016/j.lungcan.2016.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyDatabases, FactualFemaleGuidelines as TopicHumansLung NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOutcome Assessment, Health CarePneumonectomyPostoperative PeriodRadiotherapySmall Cell Lung CarcinomaSurvival AnalysisConceptsStage I small cell lung cancerClinical stage ISmall cell lung cancerCell lung cancerAdjuvant chemotherapySurgical resectionPathologic upstagingStage IRadiation therapyNodal diseaseLung cancerPositive lymph node involvementNational Cancer DatabaseOutcomes of patientsLymph node involvementProportion of patientsCurative intentNodal upstagingSCLC patientsUpstaged patientsAdjuvant therapyNode involvementIndependent predictorsInferior survivalT descriptorThe Eighth Edition Lung Cancer Stage Classification
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. CHEST Journal 2016, 151: 193-203. PMID: 27780786, DOI: 10.1016/j.chest.2016.10.010.Peer-Reviewed Original ResearchConceptsLung cancer stage classificationCancer stage classificationCohort of patientsAnatomic extentContemporary patientsLung cancerClinical studiesStage classificationEighth editionSpecific patientPatientsInternal validationCancerStage classification systemMultiple assessmentsClassification systemCohortCliniciansRole of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumorsThe differential impact of preoperative comorbidity on perioperative outcomes following thoracoscopic and open lobectomies
Jawitz OK, Wang Z, Boffa DJ, Detterbeck FC, Blasberg JD, Kim AW. The differential impact of preoperative comorbidity on perioperative outcomes following thoracoscopic and open lobectomies. European Journal Of Cardio-Thoracic Surgery 2016, 51: 169-174. PMID: 27458143, DOI: 10.1093/ejcts/ezw239.Peer-Reviewed Original ResearchConceptsNationwide Inpatient SampleOpen lobectomyPostoperative lengthVATS lobectomyLobectomy patientsVideo-assisted thoracoscopic surgery lobectomyBenign lung conditionsOpen lobectomy patientsPerioperative pulmonary complicationsVATS lobectomy patientsNumber of comorbiditiesNon-elective admissionsCell lung cancerMultivariable logistic regressionThoracoscopic surgery lobectomyStandard of careUtilization Project databasePreoperative patient comorbiditiesCumulative incidence modelsLogistic regression modellingHospital mortalityPreoperative comorbiditiesPulmonary complicationsGreater comorbidityPerioperative outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply